Radiopharmaceutical developer PETNet, an FDG supplier, has made commitments to open new manufacturing centers and supply radiopharmaceuticals to new customers across the U.S. PETNet two weeks ago announced the signing of a two-way licensing agreement
Radiopharmaceutical developer PETNet, an FDG supplier, has made commitments to open new manufacturing centers and supply radiopharmaceuticals to new customers across the U.S.
PETNet two weeks ago announced the signing of a two-way licensing agreement with Merck for radiopharmaceutical supplies.
Under the agreement, PETNet supplies Merck with radioisotopes, and PETNet obtains rights for new diagnostic radiotracer agents that may be developed by Merck.
Also under the terms of the supply contract, PETNet will open a radiopharmaceutical manufacturing and distribution center near Mercks research and development division in West Point, PA.
This site will produce and supply certain radiotracers for Mercks research and development operation.
The facility will also provide radiopharmaceuticals to other PET scanning centers in Philadelphia and surrounding areas.
PET radiotracers have a half-life of less than two hours, so they must be manufactured close to PET scanning centers. PETNet operates 15 sites throughout the U.S. that use cyclotrons to manufacture radiopharmaceuticals.
In an unconnected agreement with U.S. Oncology, PETNet will supply FDG to U.S. Oncologys one PET imaging site in Dallas. U.S. Oncology is a network of 800 oncologists in 60 cancer centers in 26 states.
The organization plans to open 30 more PET sites within the next two years.
Staff at the M.D. Anderson Cancer Center in Houston said PETNet will help them study PETs diagnostic capabilities more closely when PETNet opens a radiopharmaceutical manufacturing and distribution center in that city.
In a separate agreement, CTI, a supplier of PET products and a major shareholder in PETNet, will supply the M.D. Anderson Cancer Center with Ecat Exact PET scanners.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
2 Commerce Drive
Cranbury, NJ 08512